A Study of LY2523355 in Participants With Breast Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the anti-tumor activity of LY2523355 relative to
ixabepilone for the treatment of metastatic or locally recurrent breast cancer using change
in tumor size as a continuous measure of response.